August 2025
1. WANG N, Salam A, Pant R, Kumar A, et al
   Blood pressure-lowering efficacy of antihypertensive drugs and their combinations: a systematic review and meta-analysis of randomised, double-blind, placebo-controlled trials.
   Lancet. 2025;406:915-925.
   

   >> Share

   
   
2. MCEVOY JW
   Optional hypertension: a new concept emerging from trials of intensive blood pressure control.
   Lancet. 2025 Aug 28:S0140-6736(25)01670-8. doi: 10.1016/S0140-6736(25)01670.
   

   >> Share

   
   
3. GUO X, Sun G, Xu Y, Zhou S, et al
   Benefit-harm trade-offs of intensive blood pressure control versus standard blood pressure control on cardiovascular and renal outcomes: an individual participant data analysis of randomised controlled trials.
   Lancet. 2025 Aug 28:S0140-6736(25)01391-1. doi: 10.1016/S0140-6736(25)01391.
   

   >> Share

   
   May 2025
4. FRIEDEN TR, Garg R, Moran AE, Whelton PK, et al
   Improved hypertension care requires measurement and management in health facilities, not mass screening.
   Lancet. 2025 May 7:S0140-6736(25)00561-6. doi: 10.1016/S0140-6736(25)00561.
   

   >> Share

   
   January 2025
5. MCCARTHY CP, Bruno RM, Rahimi K, Touyz RM, et al
   Global and European landscape of major hypertension guidelines.
   Lancet. 2025 Jan 15:S0140-6736(24)02795-8. doi: 10.1016/S0140-6736(24)02795.
   

   >> Share

   
   October 2024
6. RODGERS A, Salam A, Schutte AE, Cushman WC, et al
   Efficacy and safety of a novel low-dose triple single-pill combination of telmisartan, amlodipine and indapamide, compared with dual combinations for treatment of hypertension: a randomised, double-blind, active-controlled, international clinical tria
   Lancet. 2024;404:1536-1546.
   

   >> Share

   
   
7. ANTONOPOULOU M, Chliveros K
   A novel low-dose triple single-pill combination for hypertension.
   Lancet. 2024;404:1496-1498.
   

   >> Share

   
   August 2024
8. 
   General and abdominal adiposity and hypertension in eight world regions: a pooled analysis of 837 population-based studies with 7.5 million participants.
   Lancet. 2024;404:851-863.
   

   >> Share

   
   July 2024
9. WERNHART M, Wiesinger C, Windpessl M, Madl-Liebenberger L, et al
   A visual diagnosis of phaeochromocytoma crisis characterised by cyclic fluctuations of blood pressure: be on the look-out for rapid changes.
   Lancet. 2024;404:375-376.
   

   >> Share

   
   
10. RAHIMI K
    Mounting evidence in favour of the lower, the better blood pressure paradigm.
    Lancet. 2024;404:216-217.
    

    >> Share

    
    June 2024
11. LIU J, Li Y, Ge J, Yan X, et al
    Lowering systolic blood pressure to less than 120 mm Hg versus less than 140 mm Hg in patients with high cardiovascular risk with and without diabetes or previous stroke: an open-label, blinded-outcome, randomised trial.
    Lancet. 2024 Jun 27:S0140-6736(24)01028-6. doi: 10.1016/S0140-6736(24)01028.
    

    >> Share

    
    
12. HAYASHI SI, Kawano Y, Morishita R, Kusano KF, et al
    Time-lagged amelioration of vascular endothelial function in malignant hypertension: different organs improved at different rates.
    Lancet. 2024;403:2630-2631.
    

    >> Share

    
    May 2024
13. JAFFAR S
    Integrated HIV, diabetes, and hypertension care in sub-Saharan Africa - Authors' reply.
    Lancet. 2024;403:2292.
    

    >> Share

    
    
14. CAI S, Xu Z, Zhao Y, Zuhlke L, et al
    Integrated HIV, diabetes, and hypertension care in sub-Saharan Africa.
    Lancet. 2024;403:2291.
    

    >> Share

    
    
15. HAVLIR D, Kamya MR, Petersen M
    Integrated HIV, diabetes, and hypertension care in sub-Saharan Africa.
    Lancet. 2024;403:2291-2292.
    

    >> Share

    
    March 2024
16. BAUDIN E, Goichot B, Berruti A, Hadoux J, et al
    Sunitinib for metastatic progressive phaeochromocytomas and paragangliomas: results from FIRSTMAPPP, an academic, multicentre, international, randomised, placebo-controlled, double-blind, phase 2 trial.
    Lancet. 2024;403:1061-1070.
    

    >> Share

    
    
17. DE LA SIERRA A, Staplin N, Ruilope LM, Baigent C, et al
    Ambulatory blood pressure monitoring and mortality - Authors' reply.
    Lancet. 2024;403:812.
    

    >> Share

    
    
18. LIU W, Ge W, Fan X, Du Y, et al
    Ambulatory blood pressure monitoring and mortality.
    Lancet. 2024;403:811-812.
    

    >> Share

    
    
19. MARTINEZ-GARCIA MA, Pengo MF, Parati G
    Ambulatory blood pressure monitoring and mortality.
    Lancet. 2024;403:810-811.
    

    >> Share

    
    
20. CHU WM, Ho HE, Wei JC
    Ambulatory blood pressure monitoring and mortality.
    Lancet. 2024;403:810.
    

    >> Share

    
    
21. LI SQ, Zhou JP, Wang Y, Li QY, et al
    Ambulatory blood pressure monitoring and mortality.
    Lancet. 2024;403:809-810.
    

    >> Share

    
    November 2023
22. JACKSON R, Rodgers A
    The ESH guidelines and missed prevention opportunities.
    Lancet. 2023;402:1729-1730.
    

    >> Share

    
    October 2023
23. MESSERLI FH, Bangalore S, Mandrola JM
    beta blockers switched to first-line therapy in hypertension.
    Lancet. 2023 Oct 13:S0140-6736(23)01733-6. doi: 10.1016/S0140-6736(23)01733.
    

    >> Share

    
    
24. KIVUYO S, Birungi J, Okebe J, Wang D, et al
    Integrated management of HIV, diabetes, and hypertension in sub-Saharan Africa (INTE-AFRICA): a pragmatic cluster-randomised, controlled trial.
    Lancet. 2023;402:1241-1250.
    

    >> Share

    
    
25. KISIGO GA, Peck RN
    Integrating HIV, hypertension, and diabetes primary care in Africa.
    Lancet. 2023;402:1211-1213.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share